Last updated: September 7, 2026
Gallium Ga-68 gozetotide is a prostate-specific membrane antigen (PSMA)-targeted diagnostic radiopharmaceutical used with positron emission tomography (PET) to detect PSMA-positive lesions in prostate cancer. In the United States, the product is marketed primarily as Illuccix by Telix Pharmaceuticals. Novartis markets the same active imaging ligand in kit form as Locametz.
The commercial market is expanding with PSMA PET adoption, but product-level revenue remains difficult to isolate because manufacturers report broader radiopharmaceutical portfolios. Telix’s company revenue increased from about A$262.6 million in 2022 to approximately A$449 million in 2023, reflecting the launch and scale-up of Illuccix and other products. Novartis reports Locametz within its radioligand and diagnostic activities rather than as a separate revenue line.[1][2]
What is gallium Ga-68 gozetotide used for?
Gallium Ga-68 gozetotide binds to PSMA, a cell-surface protein expressed at high levels in most prostate cancer cells. After administration, PET imaging identifies PSMA-positive sites in the prostate, lymph nodes, bone and visceral organs.
The main clinical uses are:
| Use |
Commercial relevance |
| Initial staging of unfavorable-risk prostate cancer |
Supports detection of nodal or distant disease before definitive treatment |
| Biochemical recurrence |
Helps localize disease after prostatectomy or radiation when prostate-specific antigen levels rise |
| Suspected metastatic disease |
Identifies PSMA-positive lesions for staging and treatment planning |
| Patient selection for PSMA-directed therapy |
Helps determine whether disease expresses the target required for radioligand treatment |
Illuccix received U.S. Food and Drug Administration approval in March 2022. Locametz received FDA approval in September 2022.[3][4] Both products are diagnostic agents, not therapeutic radioligands.
The diagnostic market is linked to the growth of PSMA-directed treatment, particularly Pluvicto, Novartis’s lutetium-177 vipivotide tetraxetan. Patients considered for Pluvicto commonly undergo PSMA PET imaging, creating a commercial relationship between diagnostic imaging volume and radioligand therapy demand.
How large is the gallium Ga-68 gozetotide market?
The market is part of the broader PSMA PET and radiopharmaceutical imaging market. Public companies do not report a consolidated global revenue figure for gallium Ga-68 gozetotide. Available commercial indicators point to a rapidly expanding U.S. market with increasing competition among PSMA PET agents.
Key demand drivers include:
- Rising prostate cancer incidence and prevalence.
- Greater adoption of PSMA PET in initial staging and recurrent disease.
- Clinical guideline support for PSMA imaging.
- Increased use of Pluvicto and other PSMA-directed therapies.
- Broader PET access and improved reimbursement.
- Expansion of radiopharmaceutical production and distribution networks.
The market remains constrained by short radionuclide half-life, specialized manufacturing, limited nuclear medicine capacity and variable reimbursement. Gallium-68 has a half-life of approximately 68 minutes, requiring production near the imaging site or reliable generator-based supply. Distribution economics therefore differ from conventional pharmaceuticals.
The market is also shifting toward a broader radiopharmaceutical platform model. Telix sells Illuccix alongside other diagnostic and therapeutic products. Novartis combines Locametz with an expanding radioligand portfolio. Lantheus markets Pylarify, an F-18 PSMA PET product with longer physical half-life and different supply characteristics.
What is the financial trajectory of gallium Ga-68 gozetotide?
Telix’s corporate financial growth is the clearest public indicator of Illuccix momentum. Telix does not provide a fully separate audited revenue series for gallium Ga-68 gozetotide in every reporting period, so company-level figures should not be treated as exact Illuccix sales.
| Fiscal year |
Telix reported revenue |
Commercial interpretation |
| 2022 |
Approximately A$262.6 million |
Initial commercial scale following Illuccix U.S. launch |
| 2023 |
Approximately A$449 million |
Strong growth from Illuccix and the wider commercial portfolio |
| 2024 |
Approximately A$630 million, based on company reporting |
Continued portfolio expansion and higher radiopharmaceutical demand |
Sources: Telix Pharmaceuticals annual and financial reports.[1][5]
Telix’s trajectory has several features:
- Illuccix established a recurring diagnostic revenue base in the United States.
- Revenue growth has been supported by commercial infrastructure, hospital contracts and radiopharmacy distribution.
- The company has reduced dependence on a single product as additional diagnostic and therapeutic products enter the portfolio.
- Gross-margin and profitability development depend on manufacturing scale, radionuclide procurement, logistics and launch costs.
Novartis does not separately disclose Locametz sales in its principal financial reporting. Its commercial significance is strategic because it supports the company’s PSMA radioligand ecosystem. Novartis reported strong growth in Pluvicto revenue, which increases the value of a reliable PSMA PET funnel even though Locametz revenue is not separately quantified.[2]
How does Illuccix compare with Locametz and Pylarify?
Illuccix and Locametz use gallium Ga-68 gozetotide. Pylarify uses fluorine F-18 piflufolastat and is marketed by Lantheus.
| Product |
Active imaging agent |
Company |
FDA status |
Supply model |
| Illuccix |
Gallium Ga-68 gozetotide |
Telix |
Approved March 2022 |
Kit-based Ga-68 preparation |
| Locametz |
Gallium Ga-68 gozetotide |
Novartis |
Approved September 2022 |
Kit-based Ga-68 preparation |
| Pylarify |
F-18 piflufolastat |
Lantheus |
Approved May 2021 |
Centralized or distributed F-18 production |
Pylarify’s longer-lived F-18 isotope can provide greater distribution flexibility than Ga-68, although it requires cyclotron production. Gallium-68 products benefit from generator-based production and kit preparation but remain sensitive to generator availability, radiopharmacy capacity and local operating schedules.
Competition is decided by more than ligand affinity. Relevant commercial factors include:
- Scanner and radiopharmacy access.
- Hospital purchasing contracts.
- Distribution radius.
- Reimbursement and payer coverage.
- Scheduling reliability.
- Radiochemist and nuclear medicine staffing.
- Clinical familiarity.
- Integration with therapeutic radioligand programs.
Illuccix has a direct commercial advantage from Telix’s focus on radiopharmaceutical distribution and manufacturing. Locametz benefits from Novartis’s position in radioligand therapy and its relationships with oncology centers. Pylarify benefits from Lantheus’s established nuclear imaging infrastructure.
What FDA regulatory status applies to gallium Ga-68 gozetotide?
Illuccix and Locametz are FDA-approved diagnostic radiopharmaceutical products for PSMA PET imaging in prostate cancer. The approvals cover preparation and administration of the finished radiolabeled product under the approved labeling.
The regulatory pathway differs from that of a conventional oral drug:
- The product is supplied as a kit or radiopharmaceutical preparation.
- The final administered agent is prepared close to the time of use.
- Quality controls must address radiochemical purity, radionuclide activity and sterility.
- Manufacturing and distribution must comply with drug, radiation-safety and nuclear pharmacy requirements.
- The short half-life creates operational dependencies that are less significant for conventional medicines.
FDA approval of a diagnostic product does not automatically guarantee broad payer coverage. Reimbursement decisions depend on coding, medical-necessity policies, local coverage, commercial payer rules and hospital economics.
What patents protect gallium Ga-68 gozetotide?
The commercial protection for gallium Ga-68 gozetotide is likely to depend on multiple layers rather than a single composition-of-matter patent. Relevant protection can include:
- PSMA-targeting ligand composition patents.
- Radiolabeling and kit formulation patents.
- Methods for preparing gallium Ga-68 gozetotide.
- Imaging methods for prostate cancer.
- Manufacturing and quality-control processes.
- Device, generator and radiopharmacy process rights.
- Trade secrets covering production, release testing and logistics.
Public FDA materials do not identify a conventional Orange Book patent listing as the primary commercial barrier for Illuccix or Locametz. Radiopharmaceutical kits can have a different patent profile from small-molecule prescription drugs sold as tablets or injectables. Regulatory exclusivity and manufacturing capability may therefore matter as much as listed patent rights.
What formulations are protected?
The commercially relevant formulation is a kit that contains the nonradioactive precursor and excipients needed for radiolabeling with gallium-68. The preparation is completed at a radiopharmacy or nuclear medicine facility.
Protection may attach to:
- Kit composition.
- Buffer systems.
- Chelation chemistry.
- Radiolabeling conditions.
- Stability during the usable time window.
- Sterility and release specifications.
The product’s commercial barrier is strengthened when proprietary kit design is combined with validated manufacturing, generator access, quality systems and hospital distribution.
Are there method-of-use patents?
Potential method-of-use coverage can relate to PSMA PET imaging for:
- Initial staging.
- Suspected recurrence.
- Localization of metastatic lesions.
- Selection of patients for PSMA-targeted therapy.
Method-of-use rights are generally narrower and more vulnerable to design-around arguments than composition claims. Diagnostic use can also raise enforcement issues because multiple parties participate in the imaging pathway, including physicians, radiopharmacies and hospitals.
When does gallium Ga-68 gozetotide lose exclusivity?
There is no single public loss-of-exclusivity date that reliably captures the commercial position of all gallium Ga-68 gozetotide products. The relevant dates depend on:
- The specific product, Illuccix or Locametz.
- Patent family and terminal-disclaimer status.
- Regulatory exclusivity attached to the approved application.
- Any pediatric exclusivity.
- Patent-term adjustments or extensions.
- The legal basis of a competing abbreviated application.
- Manufacturing approval and supply capability.
A conventional generic launch is also less straightforward than for a tablet. A competing company must obtain approval for the relevant kit or radiopharmaceutical, establish radiolabeling and quality systems, and secure a reliable Ga-68 supply chain.
What is the Orange Book status?
The Orange Book remains relevant for FDA-listed patents and Paragraph IV litigation, but the commercial risk analysis for gallium Ga-68 gozetotide requires review of the applicable FDA listing and product-specific patent records. Publicly available product information does not establish a well-known Orange Book patent cliff comparable to major oral oncology drugs.
Are there Paragraph IV challenges or patent lawsuits?
No major publicly reported Paragraph IV challenge or high-profile patent litigation involving Illuccix or Locametz has defined the market through the latest broadly reported company and FDA materials.
The absence of visible Paragraph IV litigation does not eliminate entry risk. A competitor could pursue:
- A competing approved radiopharmaceutical kit.
- A different PSMA ligand.
- An F-18 PSMA product.
- A hospital-compounded or institutionally prepared alternative where legally permitted.
- A product that avoids asserted formulation or process claims.
The more immediate competitive threat is product substitution rather than a traditional generic tablet launch. Pylarify already provides an approved alternative, and future PSMA PET agents could compete on isotope, image quality, throughput, supply reliability or reimbursement.
What manufacturing and IP barriers affect the market?
The strongest barriers are operational.
Manufacturing constraints
Gallium-68 products require:
- GMP or equivalent radiopharmaceutical manufacturing.
- Validated kit production.
- Access to gallium-68 generators or other radionuclide sources.
- Timely radiolabeling.
- Sterile production and release testing.
- Specialized transportation.
- Hospital or radiopharmacy infrastructure.
A product can have limited commercial value if it cannot be delivered within the isotope’s short usable period.
Intellectual-property constraints
IP risk is distributed across ligand chemistry, chelation, kit design, production methods and imaging applications. A new entrant may avoid one patent family but still face manufacturing, regulatory or freedom-to-operate barriers elsewhere in the process.
This creates a more complex entry environment than the standard generic model. The product’s commercial durability is supported by regulatory know-how and logistics, not only by patent duration.
Which companies are challenging gallium Ga-68 gozetotide?
The main competitive companies are:
| Company |
Product or platform |
Competitive position |
| Lantheus |
Pylarify, F-18 piflufolastat |
Direct PSMA PET competitor with F-18 supply characteristics |
| Novartis |
Locametz and Pluvicto ecosystem |
Integrated diagnostic and therapeutic radioligand strategy |
| Telix |
Illuccix and other radiopharmaceuticals |
Commercial Ga-68 imaging platform and growing therapeutic pipeline |
| Bracco |
Diagnostic radiopharmaceutical and imaging operations |
Potential infrastructure and distribution competitor |
| Regional radiopharmaceutical producers |
Various PSMA PET products and preparations |
Local competition based on supply and hospital relationships |
The competitive landscape is likely to remain fragmented by geography. In the United States, national distribution and FDA approval matter. In Europe and other markets, local nuclear medicine networks, reimbursement and country-specific approvals have greater influence.
What generic launch risks exist?
A direct generic launch is less likely to follow the timing pattern of a conventional oral drug. The principal risks are:
- A competing Ga-68 kit obtains FDA approval.
- An F-18 PSMA product captures imaging volume.
- Hospitals consolidate purchasing around a radioligand supplier.
- Payers favor lower-cost imaging pathways.
- Supply disruptions reduce confidence in a particular product.
- New PSMA tracers produce better operational or diagnostic performance.
- Diagnostic demand fails to grow as quickly as therapeutic radioligand demand.
The largest near-term risk is competitive substitution. The market does not require a legally identical generic to pressure price or utilization.
What is the revenue exposure for Telix and Novartis?
Telix has greater direct revenue exposure to Illuccix because the product is part of its commercial radiopharmaceutical base. A decline in Illuccix utilization would affect Telix’s diagnostic revenue, although diversification into other imaging and therapeutic products reduces concentration risk.
Novartis has lower disclosed revenue exposure to Locametz as a standalone product because the company does not report it separately. Its economic exposure is broader and more strategic: PSMA PET supports patient identification for Pluvicto and reinforces Novartis’s radioligand treatment platform.
For investors, the more important metrics are:
- PET procedure growth.
- U.S. site activation.
- Reimbursement expansion.
- Radiopharmacy capacity.
- Pluvicto treatment volumes.
- Diagnostic product gross margin.
- Product concentration within Telix.
- Competition from F-18 PSMA agents.
- Manufacturing and radionuclide supply reliability.
How strong is the commercial and patent estate?
The commercial estate is strong in the United States because Illuccix and Locametz are FDA-approved, the products address a growing clinical use case and the market has established competitors that validate demand.
The patent estate is harder to rank using only public product-level disclosures. A defensible assessment must distinguish:
- Composition protection.
- Kit and formulation protection.
- Process claims.
- Diagnostic method claims.
- Regulatory exclusivity.
- Manufacturing know-how.
- Distribution scale.
The strongest practical protection is the combination of approval, validated production, hospital relationships and radionuclide logistics. Patent expiry alone may not determine entry timing.
Key Takeaways
- Gallium Ga-68 gozetotide is a PSMA PET diagnostic agent used in prostate cancer imaging.
- Illuccix is Telix’s principal U.S. commercial product; Locametz is Novartis’s competing kit.
- FDA approvals were granted in March 2022 for Illuccix and September 2022 for Locametz.
- Telix revenue rose from about A$262.6 million in 2022 to approximately A$449 million in 2023, with continued growth reported in 2024.
- Novartis does not separately disclose Locametz revenue.
- Pylarify is the leading direct alternative and uses F-18 rather than Ga-68.
- The principal entry barriers are radiopharmaceutical manufacturing, radionuclide supply, regulatory approval and distribution.
- No single public Orange Book patent cliff clearly defines the market.
- Generic risk is less important than substitution by competing PSMA PET products.
- The diagnostic market is commercially linked to growth in Pluvicto and other PSMA-directed therapies.
FAQs
Is gallium Ga-68 gozetotide the same as Illuccix?
Yes. Illuccix is a Telix product containing the PSMA-targeting precursor used to prepare gallium Ga-68 gozetotide for PET imaging.
Is Locametz a treatment for prostate cancer?
No. Locametz is a diagnostic kit used to prepare gallium Ga-68 gozetotide for PSMA PET imaging. It does not deliver therapeutic radiation to tumors.
Does Pluvicto increase demand for gallium Ga-68 gozetotide?
Yes. PSMA PET imaging can help identify patients whose tumors express PSMA and may support treatment selection for Pluvicto. The relationship increases the strategic value of PSMA diagnostics, although it does not convert diagnostic revenue into Pluvicto revenue.
Which isotope is more commercially advantageous, Ga-68 or F-18?
The answer depends on the supply network. Ga-68 can support generator-based production near the imaging site, while F-18 has a longer half-life and can support wider distribution from cyclotron facilities. Hospital throughput, geography and radiopharmacy infrastructure determine the commercial advantage.
Will gallium Ga-68 gozetotide face a conventional generic cliff?
Probably not in the same form as a conventional tablet. Competitive pressure is more likely to come from other approved PSMA PET tracers, including F-18 products, and from new radiopharmaceutical kits with alternative manufacturing or supply models.
References
-
Telix Pharmaceuticals Limited. (2024). Annual report 2023.
-
Novartis AG. (2024). Annual report 2023.
-
U.S. Food and Drug Administration. (2022). Illuccix: Prescribing information.
-
U.S. Food and Drug Administration. (2022). Locametz: Prescribing information.
-
Telix Pharmaceuticals Limited. (2025). Annual report 2024.
-
U.S. Food and Drug Administration. (2021). Pylarify: Prescribing information.
